ClinicalTrials.gov
ClinicalTrials.gov Menu

HPV in Adolescents

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01788852
Recruitment Status : Completed
First Posted : February 11, 2013
Last Update Posted : April 1, 2015
Sponsor:
Collaborators:
Thai Red Cross AIDS Research Centre
Chulalongkorn University
South East Asia Research Collaboration with Hawaii
We Understand Group
TREAT Asia
Information provided by (Responsible Party):
The HIV Netherlands Australia Thailand Research Collaboration

Study Description
Go to 
Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
This study will assess the prevalence of HPV infection in perinatally HIV-infected adolescents, intraepithelial neoplasia, and E6E7 biomarker at cervical and anal sites.

Condition or disease
HPV Infection Cervical/Anal Dysplasia

Detailed Description:
Human Papillomavirus (HPV) is the most common sexually transmitted disease and it causes cervical and anal cancer. Prevalence and incidence of HPV infection among young adults who are sexually experienced is high. No data exist for HIV-positive adolescents in regards to HPV infection, cervical and anal intraepithelial neoplasia. This study will compare the prevalence of HPV infection, intraepithelial neoplasia and E6/E7 biomarker at cervical and anal sites among perinatally HIV-infected adolescents, behaviorally HIV-infected adolescents, and HIV-negative adolescents.

Study Design
Go to 
Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Study Type : Observational
Actual Enrollment : 27 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Prevalence of HPV and Intraepithelial Neoplasia Biomarkers in Adolescents
Study Start Date : December 2010
Actual Primary Completion Date : December 2012
Actual Study Completion Date : December 2012

Resource links provided by the National Library of Medicine

MedlinePlus related topics: HIV/AIDS
U.S. FDA Resources

Groups and Cohorts
Go to 
Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Group/Cohort
Perinatally HIV-infected adolescents
Perinatally HIV-infected adolescents
behaviorally HIV-infected adolescents
behaviorally HIV-infected adolescents
HIV negative adolescents
HIV negative adolescents


Outcome Measures
Go to 
Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. HPV infection [ Time Frame: 48 weeks ]
    Prevalence of cervical and anal HPV infection and of oncogenic subtypes, among perinatally HIV-infected adolescents, behaviorally HIV-infected adolescents, and HIv-negative adolescents


Secondary Outcome Measures :
  1. intraepithelial neoplasia [ Time Frame: 48 weeks ]
    Prevalence of intraepithelial neoplasia among the three study groups and in male and female subjects

  2. E6/E7 [ Time Frame: 48 weeks ]

    Prevalence of detected E6/E7 biomarker among the tree study groups and in male and female subjects.

    Correlation between detected E6/E7 and presence of HPV infection and/or intraepithelial neoplasia Association between HAART use, CD4 counts, plasma HIV RNA level and HIV clinical staging with HPV infection, intraepithelial neoplasia and E6/E7 detection


  3. HPV vaccine [ Time Frame: 48 weeks ]
    Proportion of adolescents who would benefit from the current preventive vaccine (i.e. those who have not been infected with oncogenic HPV subtypes 16 and 18)


Biospecimen Retention:   Samples With DNA
Cervical and anal pap smears specimens will be used for HPV typing. Blood will be collected for STI and immune response to HPV/HIV testing

Eligibility Criteria
Go to 
Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   12 Years to 24 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
A total of 60 sexually active adolescents (perinatally and behaviorally HIV-infected adolescents, HIV negative adolescents) aged 12-24 will be recruited from the HIV-NAT and TRC Anonymous Clinic
Criteria

Inclusion Criteria:

  • Perinatally-infected (documented positive HIV enzyme immunoassay (EIA) or nucleic acid testing (NAT) at any time and history of maternal HIV infection)
  • behaviorally-infected (documented positive HIV enzyme immunoassay (EIA) or nucleic acid testing (NAT) at any time after sexual debut without history of maternal HIV infection)
  • female with vaginal or receptive anal intercourse with a male OR male with receptive rectal intercourse with another male
  • Signed informed consent. Volunteers aged 12-17 years can decide whether they wish for their parents to consent for their participation. Due to the confidential nature of the issues being studied, parental consent may be exempted

Exclusion Criteria:

  • Have any conditions that may interfer with subjects' ability to understand and consent to the study
Contacts and Locations
Go to 
Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01788852


Locations
Thailand
Department of Pediatrics, Chulalongkorn University
Bangkok, Thailand, 10330
HIV-NAT
Bangkok, Thailand, 10330
Thai Red Cross - Anonymous Clinc
Bangkok, Thailand, 10330
Sponsors and Collaborators
The HIV Netherlands Australia Thailand Research Collaboration
Thai Red Cross AIDS Research Centre
Chulalongkorn University
South East Asia Research Collaboration with Hawaii
We Understand Group
TREAT Asia
Investigators
Principal Investigator: Jintanat Ananworanich, MD, PhD The HIV Netherlands Australia Thailand Research Collaboration
Principal Investigator: Nittaya Phanuphak, MD Thai Red Cross AIDS Research Centre
More Information
Go to 
Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Additional Information:
HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT)'s website  This link exits the ClinicalTrials.gov site

Responsible Party: The HIV Netherlands Australia Thailand Research Collaboration
ClinicalTrials.gov Identifier: NCT01788852     History of Changes
Other Study ID Numbers: HIV-NAT 139
First Posted: February 11, 2013    Key Record Dates
Last Update Posted: April 1, 2015
Last Verified: March 2015

Keywords provided by The HIV Netherlands Australia Thailand Research Collaboration:
HPV
HIV
cervical/anal dysplasia
intraepithelial neoplasia
 E6/E7 biomarker
perinatally HIV-infected adolescents
behaviorally HIV-infected adolescents
anal and pap smear

Additional relevant MeSH terms:
Papillomavirus Infections
DNA Virus Infections
Virus Diseases
Tumor Virus Infections